PD patients carrying LRRK2 G2019S mutation had a higher overall cancer risk (Agalliu et al., 2015) Although LRRK2 somatic mutations were demonstrated in human melanomas (Inzelberg et al., 2016b), melanoma is not among specific cancers that have been associated with LRRK2 mutations, which include leukemia, colon and skin cancer (Agalliu et al., 2019), breast cancer in women (Agalliu et al., 2015), and non-skin cancers (Inzelberg et al., 2012). This evidence concerns the gene LRRK2 and cancer.